• FDA and EMA accept marketing application for Pfizer’s talazoparib pharmaceutical-technology
    June 13, 2018
    The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted Pfizer’s marketing authorisation application for its talazoparib drug to treat metastatic breast cancer patients with an inherited BRCA mutation.
PharmaSources Customer Service